Search

Search Constraints

You searched for: Author/Creator Heerspink, Hiddo J.L.

Search Results

2. Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. Issue 2 (February 2022)

3. Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial. Issue 8 (August 2022)

4. An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials. (1st February 2021)

5. Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease. Issue 2 (February 2022)

6. Baseline characteristics and enrichment results from the SONAR trial. Issue 8 (1st May 2018)

7. Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial. Issue 18 (8th February 2021)

8. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial. Issue 9 (27th August 2019)

10. Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD. Issue 11 (November 2022)